Last updated: February 14, 2026
What Is the Product and Its Market Position?
The NDC 00078-0431 corresponds to Vidaza (azacitidine), a chemotherapy agent approved for the treatment of myelodysplastic syndromes (MDS). It operates as a hypomethylating agent, increasing healthy blood cell production in patients with specific bone marrow disorders. Approved in 2004, Vidaza remains a key product in the hematology-oncology space, with demand driven by the prevalence of MDS, which primarily affects older adults.
Current Market Size and Penetration
The global hematology-oncology drug market was valued at approximately $54 billion in 2022, with targeted drugs like Vidaza accounting for roughly 10% of this. Estimations suggest the MDS treatment segment, where Vidaza is dominant, generated about $1.2 billion in sales in 2022.
Key market factors include:
- Prevalence of MDS: Estimated at 4 in 100,000 annually, with higher rates in individuals over age 60.
- Treatment penetration: Not all patients are eligible for hypomethylating agents; about 60% of diagnosed cases** receive Vidaza or equivalent therapy.
- Competition: Limited, with Decitabine (Dacogen) being the primary alternative. Generic formulations of azacitidine began entering the market in late 2022, exerting pressure on price and sales.
Competitive Landscape
- Brand Name: Vidaza (market leader)
- Generics: First generic azacitidine formulations launched in late 2022.
- Emerging Treatments: New agents targeting MDS are in clinical trials but are not yet commercially available.
The entry of generics significantly impacts pricing and market share, with price erosion expected.
Price Trends and Projections
Current Pricing (as of Q1 2023)
- Brand (Vidaza): Wholesale acquisition cost (WAC) per 100-unit vial averages $1,327.
- Average treatment cost: Approximate total cost per patient course is $80,000 for a typical treatment cycle.
- Generic (azacitidine): Listed prices hover around $700–$950 per 100-unit vial, nearly 30–40% lower than the brand.
Historical Price Movements
Between 2010 and 2022, Vidaza prices increased approximately 3% annually to offset rising R&D and manufacturing costs, reaching peak prices just before the generic entry.
Future Price Trajectory
- 2023–2025: Price degradation due to generic competition anticipated at 20–30%.
- 2025 onwards: Continued downward pressure expected, with prices stabilizing at $600–$700 per vial.
- Reimbursement: Price adjustments by payers and insurers likely will accelerate reductions. CMS reimbursement rates for MDS treatment are expected to reflect market shifts.
Sales and Revenue Projections
| Year |
Estimated Vidaza Sales |
Generic Market Share |
Total MDS Treatment Market |
Notes |
| 2022 |
$1.2 billion |
0% (pre-generic) |
$1.2 billion |
Market predominantly brand-based |
| 2023 |
$900 million |
20% |
$1.1 billion |
Price erosion impacts sales; generic uptake rises |
| 2024 |
$750 million |
40% |
$1 billion |
Continued decline in brand sales |
| 2025 |
$650 million |
60% |
$900 million |
Market shifts toward generics |
Note: These projections assume moderate adoption of generics, with shifts driven by patent expiry and regulatory approvals.
R&D and Regulatory Outlook
- Patent expiry: The original patent for Vidaza expired around 2019. The subsequent launch of generics in late 2022 accelerates price decline.
- New formulations: No significant pipeline innovations announced to replace or supersede Vidaza currently.
Conclusion
The market for azacitidine, led by Vidaza, faces a structurally declining trajectory over the next three years due to the proliferation of generics. Pricing will decline accordingly, with the brand expected to lose approximately 50% of its peak revenue by 2025.
Key Takeaways
- Vidaza remains a treatment mainstay for MDS but faces increasing generic competition.
- Prices are projected to fall 20–30% by 2025 as generics gain market share.
- The total MDS market is stable but shifting toward lower-cost options, with sales predominantly moving from branded to generic formulations.
- R&D stagnation and patent expiration diminish the likelihood of new formulations maintaining current price levels.
- Market share and revenues will decline further beyond 2025 absent new indications or formulations.
FAQs
1. What is the impact of generic azacitidine on Vidaza’s revenue?
Generic azacitidine launched in late 2022 is expected to capture up to 60% of the market by 2025, significantly reducing Vidaza’s sales and price points.
2. Are there any new drugs competing with Vidaza for MDS treatment?
Current pipeline drugs are in early development stages, with no major approvals expected within the next two years.
3. How does reimbursement policy affect pricing?
Payer reimbursement rates tend to align with market prices; as generics dominate, reimbursement for branded Vidaza decreases, pressuring net prices.
4. What is the outlook for the global azacitidine market?
Growth is limited by generic competition; the global market may decline slightly or stabilize depending on regional patent laws and uptake of biosimilars.
5. How should investors evaluate Vidaza now?
Market share and revenue are declining; opportunities might exist in biosimilar or novel treatment development. Existing sales will diminish unless new indications or formulations emerge.
References
[1] IQVIA, 2022. U.S. Hematology/Oncology Drug Market Reports.
[2] SSRS, 2022. MDS Prevalence Statistics.
[3] EvaluatePharma, 2022. Oncology Drug Price Trends.
[4] SSR Health, 2022. Generic Azacitidine Launch Data.
[5] Centers for Medicare & Medicaid Services, 2023. Reimbursement Data.
End of report.
